Gastric Cancer Clinical Trial
— NICEOfficial title:
Efficacy and Safety of Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer : a Open-label, Phase 2 Randomised Controlled Trial (NICE Trial)
For locally advanced esophagogastric junction and gastric cancer (cT3-4aNxM0 or cT2N+M0), neoadjuvant chemotherapy can downstage T and N stage,treated distant micrometastases early before local therapy has begun, and finally improve the long-term survival. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced esophagogastric junction and gastric cancer could be a novel therapy to increase response rate and reduce recurrence rate. JS001 in this study is a Chinese anti-PD-1 monoclonal antibody for injection which has been approved for melanoma. This study is a multi-center, open-label, randomized phase II clinical trial to evaluate safety and efficacy of JS001 in combination with perioperative chemotherapy in locally advanced esophagogastric junction and gastric cancer. Differences in gut microbiome and tumor immune microenvironment were detected to screen people who were more sensitive to immunotherapy.
Status | Recruiting |
Enrollment | 110 |
Est. completion date | December 30, 2024 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Written (signed) informed consent; 2. Age = 18 years and =75 years. 3. Confirmed gastric and gastroesophageal junction adenocarcinoma by Gastroscopic biopsy histopathological examination. 4. Imaging (CT/MRI) and diagnostic laparoscopy confirmed at the stage of cT3/4a Nx or T2 N+, M0(AJCC 8th) before randomization. 5. confirmed by immunohistochemistry (IHC) staining or genetic and transcriptional profiling detection to meet one of the following conditions: 1. Combined positive score (CPS) of PD-L1 protein expression =5. 2. Epstein-Barr virus-positive (EBV(+)). 3. mismatch repair-deficient (dMMR). 4. Microsatellite instability-high (MSI-H) 6. The Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1 7. Expected survival period = 12 weeks 8. The main organ function meets the following criteria within 7 days before treatment: 1. Hemoglobin (Hb) level =9.0 g/dl 2. Neutrophil count (ANC)=1.5×l09/L 3. Platelet (PLT) =100×109/L 4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level =2.5×ULN 5. Alkaline phosphatase(ALP)level =2.5×ULN 6. Serum creatinine (Cr) level =1.5×ULN and creatinine clearance =60 ml/min 7. Thyroid stimulating hormone (TSH) level =1×ULN (if abnormal, should require normal serum free thyroid hormone (T4) and Normal serum free triiodothyronine (T3)) Exclusion Criteria: 1. Confirmed at stage IV (AJCC 8th) or unresectable by investigator before randomization. 2. Prior chemotherapy, radiotherapy, surgery immunotherapy or molecular targeted therapy for gastric cancer; 3. Patients who have HER2 positive confiemed with IHC3+ or IHC2+ and FISH positive 4. Patients are allergic to study medication and its ingredients 5. Patients with a history of following treatments: 1. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent 2. Prior therapy with tyrosine kinase inhibitor within 2 weeks. 3. Patients who have participated in other clinical trials of anti-tumor drugs within four weeks 4. Have vaccination with attenuated live vaccines within 4 weeks prior to initiation of the study treatment or plan to vaccinate during the study; 5. Concurrent medical condition requiring the use of cortisol (>10mg/day Prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment. Except: inhalation or topical corticosteroids. Doses > 10 mg/day prednisone or equivalent for replacement therapy 6. Patients have experienced or currently has other malignancies within 5 years. 7. Patients have an active or history of autoimmune disease that may recur or require immunosuppressive drugs within 2 weeks or less or during the study. Or have a history of immunodeficiency, including HIV-positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation 8. Patients with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial. 9. Within 2 weeks or 2 weeks before randomization, patients have an active or uncontrollable infection that requires systemic antibiotic treatment 10. Diagnosed with interstitial pneumonia, non-infectious pneumonia, pulmonary fibrosis, acute lung disease; 11. Patients with active tuberculosis or receiving previous anti-tuberculosis therapy within one year 12. Women who are pregnant, breast-feeding or planning to become pregnant during treatment or within 6 months after treatment ends. 13. Patients have a history of psychotropic substance abuse and are unable to quit or have a mental disorder |
Country | Name | City | State |
---|---|---|---|
China | Fujian Provincial Hospital | Fuzhou | Fujian |
China | Guangdong Provincial Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, | Guangzhou | Guangdong |
China | Nanfang Hospital, Southern Medical University | Guangzhou | Guangdong |
China | The six affiliated hospital, Sun Yat-sen University | Guangzhou | Guangdong |
China | Harbin Medical University Cancer Hospital | Harbin | Heilongjiang |
China | Mao ming people's hospital | Maoming | Guangdong |
China | Peking University Shenzhen Hospital | Shenzhen | Guangdong |
China | The Eighth Affiliated Hospital, Sun Yat-Sen University | Shenzhen | Guangdong |
China | The First Affiliated Hospital of Xiamen University | Xiamen | Fujian |
China | Zhongshan People's Hospital | Zhongshan | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Nanfang Hospital of Southern Medical University | Shanghai Junshi Bioscience Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Major pathologic response (MPR) | It is defined as residual tumors less than 10% after neoadjuvant immunotherapy and(or) chemotherapy | From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 14 weeks | |
Secondary | Disease-free survival (DFS) | The Kaplan-Meier survival from the initiation date of first cycle until the date of first documented recurrence. | From the initiation date of first cycle (each cycle is 21 days) to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years | |
Secondary | Overall survival(OS) | From date of randomization until the date of first documented date of death from any cause, assessed up to 36 months | ||
Secondary | pCR | Pathological complete response after neoadjuvant immunotherapy and(or) chemotherapy | From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 14 weeks | |
Secondary | R0 resection rate | Rate of microscopically margin-negative resection | From the initiation date of first cycle (each cycle is 21 days) to the date of operation, an average of 14 weeks | |
Secondary | Adverse event incidence rate | Number of participants with treatment-related adverse events as assessed by National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v4.03 | Patients will be assessed for adverse events throughout the study at every visit during treatment and at 3-month follow-up visit (3 months after treatment ends) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |